Welcome to Paid Research Studies




  • Condition:   Urethral Stricture
    Intervention:   Procedure: Urethroplasty
    Sponsor:   University Hospital, Ghent
    Not yet recruiting

  • Condition:   Urethral Stricture
    Interventions:   Device: Optilume Drug Coated Balloon (DCB);   Device: Control Treatment
    Sponsors:   Urotronic Inc.;   ClinLogix. LLC
    Recruiting

  • Condition:   Urethral Obstruction
    Intervention:   Procedure: Fetal Intervention for LUTO
    Sponsor:   Baylor College of Medicine
    Recruiting

  • Conditions:   Fibroid Uterus;   Urethral Diseases;   Sex Disorder
    Intervention:   Procedure: urethral length measure
    Sponsor:   Medical University of Lublin
    Recruiting

  • Conditions:   Pelvic Fracture;   Urethra Tear;   Urethra Injury Male;   Trauma;   Surgery
    Intervention:  
    Sponsor:   University of Utah
    Recruiting

  • Conditions:   Urethral Stricture;   Surgery;   Urologic Diseases
    Interventions:   Procedure: Transecting anastomotic repair (tAR);   Procedure: Vessel-sparing anastomotic repair (vsAR)
    Sponsor:   University Hospital, Ghent
    Recruiting

  • Conditions:   Pain, Postoperative;   Urethral Stricture
    Interventions:   Drug: Oxycodone;   Drug: Acetaminophen;   Drug: Gabapentin;   Drug: celebrex;   Drug: Bupivacaine;   Drug: Ibuprofen 800 mg;   Drug: Dexamethasone
    Sponsor:   University of Alabama at Birmingham
    Recruiting

  • Conditions:   Benign Prostatic Hyperplasia (BPH);   Prostate Cancer
    Intervention:   Device: Prostatic Urethral Lift (PUL)
    Sponsor:   Case Comprehensive Cancer Center
    Not yet recruiting

  • Conditions:   Urethra Issue;   Pelvic Organ Prolapse;   Urinary Incontinence;   Vaginal Vault Prolapse;   Cystocele;   Uterine Prolapse;   Vaginal Prolapse;   Pelvic Floor Disorders
    Interventions:   Drug: Water-Based Vaginal Lubricant;   Drug: lidocaine topical
    Sponsor:   University of Texas Southwestern Medical Center
    Not yet recruiting

  • Conditions:   Anesthesia;   Urethral Obstruction
    Interventions:   Drug: Placebo;   Drug: Gabapentin
    Sponsor:   Northwestern University
    Recruiting

  • Condition:   Pelvic Pain Syndrome
    Interventions:   Procedure: Electrical pudendal nerve stimulation;   Procedure: Intravesical instillation
    Sponsor:   Shanghai Institute of Acupuncture, Moxibustion and Meridian
    Recruiting

  • Condition:   Prostate Cancer
    Intervention:   Device: 16 French Foley Catheter
    Sponsor:   University of Alabama at Birmingham
    Recruiting

  • Conditions:   Prostate Cancer;   Urinary Incontinence
    Interventions:   Procedure: SFUR-RARP;   Procedure: Standard RARP
    Sponsor:   Changhai Hospital
    Not yet recruiting

  • Condition:   Intermittent Urethral Catheterization
    Intervention:   Other: Self questionnaire
    Sponsor:   Gérard Amarenco
    Recruiting

  • Condition:   Recurrent Urinary Tract Infection
    Interventions:   Procedure: Rigid cystoscopy with urethral dilatation;   Procedure: Flexible cystoscopy and installation of Glycosaminoglycan layer replacement (laluril)
    Sponsor:   Hampshire Hospitals NHS Foundation Trust
    Recruiting

  • Conditions:   Pain;   Stress Incontinence, Female
    Interventions:   Drug: Nitrous Oxide + Oxygen Gas (Product);   Drug: lidocaine gel 2%;   Other: Room air
    Sponsor:   Baylor Research Institute
    Recruiting

  • Condition:   Stress Urinary Incontinence
    Intervention:   Procedure: mid urethral sling surgery
    Sponsor:   Ankara University
    Not yet recruiting

  • Conditions:   Stress Urinary Incontinence;   Fecal Incontinence
    Interventions:   Drug: Citalopram 40mg;   Drug: Reboxetine 8 mg;   Drug: Placebo oral tablet
    Sponsor:   University Hospital Bispebjerg and Frederiksberg
    Recruiting

  • Conditions:   Stress Urinary Incontinence;   Pelvic Floor Disorders
    Interventions:   Device: RP sling placement;   Device: SIS placement
    Sponsors:   Wake Forest University Health Sciences;   Foundation for Female Health Awareness
    Recruiting

  • Condition:   Urethral Catheter Removal After Urologic Procedure
    Interventions:   Procedure: Room temperature saline instillation;   Procedure: Warmed saline instillation;   Procedure: No saline instillation
    Sponsor:   Ronald Kaufman, MD
    Recruiting

  • Conditions:   Stage I Prostate Adenocarcinoma;   Stage II Prostate Adenocarcinoma
    Interventions:   Radiation: Radiation Therapy Treatment Planning and Simulation;   Radiation: SBRT
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lower Urinary Tract Dysfunction;   Overactive Bladder Syndrome
    Intervention:  
    Sponsors:   Far Eastern Memorial Hospital;   National Science Council, Taiwan
    Recruiting

  • Conditions:   Urinary Bladder Neoplasms;   Ureteral Neoplasms;   Urethral Neoplasms
    Intervention:   Drug: Crizotinib
    Sponsors:   Earle Burgess;   Pfizer
    Recruiting

  • Conditions:   Point-of-Care Bladder Ultrasound;   Urethral Catheter
    Interventions:   Device: Bladder Ultrasound;   Other: Standard of Care
    Sponsor:   University of Alabama at Birmingham
    Recruiting

  • Conditions:   Complications; Urethral Catheter;   Ureteral Catheterization;   Ureteroscopy;   Lower Urinary Tract Symptoms;   Flank Pain
    Intervention:   Procedure: urethral catheter placement
    Sponsor:   Marmara University
    Recruiting

  • Conditions:   Menopausal Urethral Atrophy;   Vulvar Atrophy
    Intervention:   Procedure: laser vaginal treatment
    Sponsors:   Sunnybrook Health Sciences Centre;   Innovation Fund of the Alternative Funding Plan from the Academic Health Sciences Centres of Ontario
    Recruiting

  • Conditions:   Distal Urethral Cancer;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Urethral Cancer;   Stage III Bladder Cancer;   Stage III Urethral Cancer;   Stage IV Bladder Cancer;   Stage IV Urethral Cancer;   Ureter Cancer
    Interventions:   Drug: afatinib dimaleate;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Melanoma;   Breast Cancer;   Uterine Cancer;   Ovarian Cancer;   Prostate Cancer;   Urethral Cancer;   Bladder Cancer;   Renal Cancer;   Lung Cancer;   Head and Neck Cancer
    Interventions:   Drug: MRx0518 Capsules;   Drug: MRx0518/placebo Capsules
    Sponsors:   Imperial College London;   4D pharma plc
    Recruiting

  • Condition:   Non-muscle-invasive Bladder Cancer
    Intervention:   Diagnostic Test: Xpert Bladder Cancer Monitor
    Sponsors:   Cepheid;   Axonal Biostatem CRO
    Recruiting

  • Conditions:   Intermittent Urethral Catheterization;   Lower Urinary Tract Symptoms;   Treatment Adherence;   Patient Satisfaction
    Intervention:   Other: Observational study
    Sponsor:   Gérard Amarenco
    Recruiting

  • Condition:   Prostate Cancer
    Interventions:   Radiation: IGRT 24 Gy Single dose;   Procedure: Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT);   Device: Rectal balloon with air filling;   Device: Urethral catheter loaded with beacon transponders
    Sponsor:   Fundacao Champalimaud
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Urothelial Carcinoma;   Bladder Cancer;   Ureter Cancer;   Urethral Cancer
    Intervention:   Biological: Immune checkpoint inhibitor targeting PD1
    Sponsor:   Fox Chase Cancer Center
    Recruiting

  • Condition:   Hypospadias
    Intervention:   Procedure: URAGPI technique
    Sponsor:   Assiut University
    Not yet recruiting

  • Conditions:   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Recurrent Bladder Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Regional Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage III Bladder Urothelial Carcinoma;   Stage III Urethral Cancer;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Urethral Cancer;   Urethral Urothelial Carcinoma
    Interventions:   Drug: Pembrolizumab;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride
    Sponsors:   University of California, Davis;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Hydronephrosis;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant;   Renal Pelvis Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage II Renal Pelvis Cancer AJCC v7;   Stage II Ureter Cancer AJCC v7;   Stage II Urethral Cancer AJCC v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Renal Pelvis Cancer AJCC v7;   Stage III Ureter Cancer AJCC v7;   Stage III Urethral Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Ureter Urothelial Carcinoma;   Urethral Urothelial Carcinoma
    Interventions:   Biological: Durvalumab;   Procedure: Therapeutic Conventional Surgery;   Biological: Tremelimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Bladder Urothelial Carcinoma;   Metastatic Renal Pelvis Urothelial Carcinoma;   Metastatic Ureter Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Metastatic Urothelial Carcinoma;   Recurrent Bladder Urothelial Carcinoma;   Recurrent Renal Pelvis Urothelial Carcinoma;   Recurrent Ureter Urothelial Carcinoma;   Recurrent Urethral Urothelial Carcinoma;   Stage III Bladder Cancer AJCC v8;   Stage III Renal Pelvis Cancer AJCC v8;   Stage III Ureter Cancer AJCC v8;   Stage III Urethral Cancer AJCC v8;   Stage IV Bladder Cancer AJCC v8;   Stage IV Renal Pelvis Cancer AJCC v8;   Stage IV Ureter Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8
    Interventions:   Drug: Atezolizumab;   Biological: Glycosylated Recombinant Human Interleukin-7;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Bladder Small Cell Neuroendocrine Carcinoma;   Castration-Resistant Prostate Carcinoma;   Metastatic Bladder Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   Prostate Neuroendocrine Neoplasm;   Prostate Small Cell Carcinoma;   Stage III Bladder Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage III Urethral Cancer AJCC v8;   Stage IV Bladder Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Ureter Small Cell Carcinoma;   Urothelial Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Docetaxel;   Drug: Etoposide;   Biological: Pembrolizumab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Clear Cell Renal Cell Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Small Cell Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Bladder Urothelial Carcinoma;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Penile Carcinoma;   Metastatic Renal Cell Carcinoma;   Metastatic Renal Pelvis Urothelial Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Ureter Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Progressive Disease;   Squamous Cell Carcinoma of the Penis;   Stage III Bladder Adenocarcinoma AJCC v6 and v7;   Stage III Bladder Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Penile Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Stage III Renal Pelvis Cancer AJCC v7;   Stage III Ureter Cancer AJCC v7;   Stage III Urethral Cancer AJCC v7;   Stage IIIa Penile Cancer AJCC v7;   Stage IIIb Penile Cancer AJCC v7;   Stage IV Bladder Adenocarcinoma AJCC v7;   Stage IV Bladder Squamous Cell Carcinoma AJCC v7;   Stage IV Bladder Urothelial Carcinoma AJCC v7;   Stage IV Penile Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Urothelial Carcinoma Bladder;   Urothelial Carcinoma Ureter;   Urothelial Carcinoma of the Renal Pelvis and Ureter;   Urothelial Carcinoma Urethra
    Interventions:   Drug: Sitravatinib;   Drug: Nivolumab
    Sponsor:   Mirati Therapeutics Inc.
    Recruiting

  • Conditions:   Carcinoma, Transitional Cell;   Urinary Bladder Neoplasms;   Urologic Neoplasms;   Renal Pelvis Neoplasms;   Urothelial Cancer;   Ureteral Neoplasms;   Urethral Neoplasms
    Interventions:   Drug: enfortumab vedotin;   Drug: pembrolizumab;   Drug: cisplatin;   Drug: carboplatin;   Drug: gemcitabine
    Sponsors:   Astellas Pharma Global Development, Inc.;   Seattle Genetics, Inc.
    Recruiting

  • Conditions:   Carcinoma, Transitional Cell;   Urinary Bladder Neoplasms;   Urologic Neoplasms;   Renal Pelvis Neoplasms;   Urothelial Cancer;   Ureteral Neoplasms;   Urethral Neoplasms
    Intervention:   Drug: Enfortumab vedotin
    Sponsors:   Astellas Pharma Global Development, Inc.;   Seattle Genetics, Inc.
    Recruiting

  • Conditions:   Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breast Cancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer;   Neuroendocrine Tumors;   Plasma Cell Dyscrasia
    Intervention:  
    Sponsor:   University of Nebraska
    Recruiting

  • Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Prostate Cancer Adenocarcinoma;   Adjuvant Radiotherapy;   Salvage Radiotherapy;   SBRT;   IGRT;   Urethral Sparing
    Intervention:   Radiation: SBRT
    Sponsor:   Fundacao Champalimaud
    Recruiting

  • Conditions:   Metastatic Bladder Urothelial Carcinoma;   Metastatic Renal Pelvis Urothelial Carcinoma;   Metastatic Ureter Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Unresectable Renal Pelvis Urothelial Carcinoma;   Unresectable Ureter Urothelial Carcinoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Biological: Pembrolizumab;   Biological: Autologous Tumor Infiltrating Lymphocytes LN-145;   Biological: Aldesleukin
    Sponsors:   Roswell Park Cancer Institute;   Iovance Biotherapeutics, Inc.
    Recruiting

  • Conditions:   Unresectable Locally Advanced Urothelial Cancer;   Metastatic Urothelial Cancer
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Drug: Cisplatin + Gemcitabine;   Drug: Carboplatin + Gemcitabine
    Sponsor:   AstraZeneca
    Recruiting

  • Condition:   Urothelial Carcinoma
    Interventions:   Drug: Atezolizumab;   Drug: Guadecitabine
    Sponsors:   Fox Chase Cancer Center;   Stand Up To Cancer;   Van Andel Research Institute
    Recruiting

  • Conditions:   Prostate Cancer;   Bladder Outlet Obstruction
    Intervention:   Device: Prostatic Artery Embolization
    Sponsor:   Dominik Abt
    Recruiting

  • Condition:   Stress Urinary Incontinence
    Interventions:   Biological: AMDC-USR;   Other: Placebo
    Sponsor:   Cook MyoSite
    Not yet recruiting

  • Condition:   Stress Urinary Incontinence
    Interventions:   Biological: AMDC-USR;   Other: Placebo
    Sponsor:   Cook MyoSite
    Recruiting

  • Condition:   Urothelial Carcinoma
    Interventions:   Drug: Avelumab;   Drug: AVB-S6-500
    Sponsors:   University of Oklahoma;   Aravive, Inc.;   EMD Serono
    Not yet recruiting

  • Conditions:   Urothelial Carcinoma;   Renal Cell Carcinoma;   Non-Small Cell Lung Cancer;   Castration-resistant Prostate Cancer;   Triple Negative Breast Cancer;   Ovarian Cancer;   Endometrial Cancer;   Hepatocellular Carcinoma;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma;   Colorectal Cancer;   Head and Neck Cancer;   Differentiated Thyroid Cancer;   Lower Esophageal Cancer
    Interventions:   Drug: cabozantinib;   Drug: atezolizumab
    Sponsor:   Exelixis
    Recruiting

  • Condition:   Recurrent/Metastatic Urothelial Cancers
    Intervention:  
    Sponsors:   Latin American Cooperative Oncology Group;   Janssen-Cilag Ltd.
    Not yet recruiting

  • Condition:   Mycoplasma Genitalium Infection
    Intervention:   Drug: Comparison of two standard of care regimens
    Sponsor:   University of Alabama at Birmingham
    Not yet recruiting

  • Conditions:   Bladder Exstrophy;   Urinary Incontinence
    Intervention:   Drug: MDC
    Sponsor:   Johns Hopkins University
    Recruiting

  • Conditions:   Humans;   Urinary Incontinence;   Male Urogenital Diseases;   Prostatectomy;   Erectile Dysfunction
    Interventions:   Device: Intraoperative nerve monitoring,;   Procedure: standard of care robotic-assisted radical prostatectomy
    Sponsor:   Herlev and Gentofte Hospital
    Recruiting